Skip to content

News

Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America

(Stockholm, May 5, 2023) On May 19, 2023 Asarina Pharma’s positive results from its Phase IIa Study in Tourette Syndrome will be presented at TicCon, the Virtual National Conference of the Tourette Association of America, by Assoc. Prof. Marco Bortolato (Dept Pharmacology & Toxicology, University of Utah). The results were an important target validation of…

Full PDF

Asarina Pharma AB (publ) releases Annual Report 2022

(Stockholm, 28 April 2023) Asarina Pharma’s 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results for Tourette syndrome, as well as 2022 financial statements and outlook. Additional content includes investor FAQs with CEO Peter Nordkild and clinical insights from Clinical Neurologist Dr Heidi Biernat (Head of the Tourette Clinic at…

Full PDF

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

The shareholders of Asarina Pharma AB (publ) reg. no. 556698-0750 (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 22 May 2023 at 10:00 CEST at Fredersen Advokatbyrå's premises at Birger Jarlsgatan 8, Stockholm. Registration starts at 09:30 CEST.

Full PDF

Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome

(Stockholm, April 1, 2023) Asarina Pharma today releases results from its Phase IIa study of the endogenous neurosteroid Sepranolone for the treatment of Tourette Syndrome. The primary objective of the study was to investigate the efficacy of Sepranolone, compared to Standard of Care, to reduce tic severity in patients with Tourette Syndrome at twelve weeks,…

Full PDF

Asarina Pharma AB (publ) releases Year-End Report 2022

(Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 the company continued its Phase IIa study in Sepranolone for Tourette Syndrome, on schedule, completing Last Patient Last Visit on February 1, less than 12 months after commencement. The patient dropout rate…

Full PDF
Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought 2022-09-05 13:24
A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been published...
Asarina Pharma AB (publ) Q2 2022 Report released 2022-08-25 08:30 Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME CEO Peter Nordkild: “If full clinical development is successful, Sepranolone will be the...
Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen 2022-06-23 11:15
On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the “Loan Agreement”)...
Asarina Pharma AB (publ) Q1 2022 Report released 2022-05-25 08:30 Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) 2022-05-04 11:29
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2021...
ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED 2022-04-06 17:25 Annual
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ) 2022-04-05 08:00
Asarina Pharma’s Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting...
Asarina Pharma AB (publ) Year-end Report 2021 released 2022-02-24 08:00 Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the clinical trial...
First patient in for landmark Tourette Syndrome study 2022-02-16 14:31
30 patients ranging from 12 to 45 years old will be taking part in a phase IIa proof-of-concept study at two major University Hospitals in Copenhagen -...
Asarina Pharma receives final approval for landmark phase IIa Tourette study 2021-12-22 15:03
The phase IIa Tourette study will take place at the Danish National Center for Tourette at Herlev University Hospital, Scandinavia’s largest Tourette...
PreviousNext